6tz3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
==Crystal Structure of Human Synaptotagmin 1 C2B without Ca2+==
==Crystal Structure of Human Synaptotagmin 1 C2B without Ca2+==
-
<StructureSection load='6tz3' size='340' side='right'caption='[[6tz3]]' scene=''>
+
<StructureSection load='6tz3' size='340' side='right'caption='[[6tz3]], [[Resolution|resolution]] 1.17&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TZ3 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TZ3 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6tz3]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TZ3 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TZ3 FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tz3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tz3 OCA], [http://pdbe.org/6tz3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tz3 RCSB], [http://www.ebi.ac.uk/pdbsum/6tz3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tz3 ProSAT]</span></td></tr>
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
 +
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1uow|1uow]]</td></tr>
 +
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">SYT1, SVP65, SYT ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tz3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tz3 OCA], [http://pdbe.org/6tz3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tz3 RCSB], [http://www.ebi.ac.uk/pdbsum/6tz3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tz3 ProSAT]</span></td></tr>
</table>
</table>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/SYT1_HUMAN SYT1_HUMAN]] May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse. It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone. A Ca(2+)-dependent interaction between synaptotagmin and putative receptors for activated protein kinase C has also been reported. It can bind to at least three additional proteins in a Ca(2+)-independent manner; these are neurexins, syntaxin and AP2.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
At neuronal synapses, synaptotagmin-1 (syt1) acts as a Ca(2+) sensor that synchronizes neurotransmitter release with Ca(2+) influx during action potential firing. Heterozygous missense mutations in syt1 have recently been associated with a severe but heterogeneous developmental syndrome, termed syt1-associated neurodevelopmental disorder. Well-defined pathogenic mechanisms, and the basis for phenotypic heterogeneity in this disorder, remain unknown. Here, we report the clinical, physiological, and biophysical characterization of three syt1 mutations from human patients. Synaptic transmission was impaired in neurons expressing mutant variants, which demonstrated potent, graded dominant-negative effects. Biophysical interrogation of the mutant variants revealed novel mechanistic features concerning the cooperative action, and functional specialization, of the tandem Ca(2+)-sensing domains of syt1. These mechanistic studies led to the discovery that a clinically approved K(+) channel antagonist is able to rescue the dominant-negative heterozygous phenotype. Our results establish a molecular cause, basis for phenotypic heterogeneity, and potential treatment approach for syt1-associated neurodevelopmental disorder.
 +
 +
Molecular Basis for Synaptotagmin-1-Associated Neurodevelopmental Disorder.,Bradberry MM, Courtney NA, Dominguez MJ, Lofquist SM, Knox AT, Sutton RB, Chapman ER Neuron. 2020 Apr 21. pii: S0896-6273(20)30272-5. doi:, 10.1016/j.neuron.2020.04.003. PMID:32362337<ref>PMID:32362337</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 6tz3" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
 +
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Dominguez MJ]]
+
[[Category: Dominguez, M J]]
-
[[Category: Karmakar S]]
+
[[Category: Karmakar, S]]
-
[[Category: Meyer AG]]
+
[[Category: Meyer, A G]]
-
[[Category: Sutton RB]]
+
[[Category: Sutton, R B]]
 +
[[Category: C2 domain]]
 +
[[Category: C2b]]
 +
[[Category: Exocytosis]]
 +
[[Category: Greek key]]

Revision as of 11:34, 22 July 2020

Crystal Structure of Human Synaptotagmin 1 C2B without Ca2+

PDB ID 6tz3

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools